{"drugs":["Blenoxane","Bleomycin Sulfate"],"mono":[{"id":"80775-s-0","title":"Generic Names","mono":"Bleomycin Sulfate"},{"id":"80775-s-1","title":"Dosing and Indications","sub":[{"id":"80775-s-1-4","title":"Adult Dosing","mono":"<ul><li>total doses greater than 400 units should be given with great caution, as pulmonary toxicity appears to be dose-related<\/li><li><b>AIDS-related Kaposi's sarcoma:<\/b> optimal dosing and timing not yet defined; clinical trials have used 0.5 units INTRALESIONALLY for tumors up to 100 mm(3) in size, 0.75 units for tumors 100 to 150 mm(3), 1 unit for tumors 150 to 500 mm(3), 1.5 units for tumors 500 to 1000 mm(3), 2 units for tumors 1000 to 2000 mm(3), 2.5 units for tumors 2000 to 3000 mm(3), 3 units for tumors 3000 to 4000 mm(3), 3.5 units for tumors 4000 to 5000 mm(3), and 4 units for tumors larger than 5000 mm(3); lidocaine 1% with epinephrine solution was injected around  the site, followed by 6 to 8 99-microsecond pulses of  electricity at an amplitude of 1.3 kV\/cm using either electrodes consisting of 2 parallel stainless steel plates mounted on a vernier caliper or a circular array of 6 needles<\/li><li><b>Carcinoma of esophagus:<\/b> Optimal dosing and timing not yet defined; clinical trials have used 10 mg\/m(2) IV on day 3 after cisplatin, followed by continuous IV infusion of 10 mg\/m(2)\/day from days 3 to 6 after cisplatin<\/li><li><b>Germ cell tumor of ovary:<\/b> optimal dose and timing of bleomycin has not been defined<\/li><li><b>Gestational trophoblastic neoplasia:<\/b> optimal dose and timing has not been defined<\/li><li><b>Hodgkin's disease:<\/b> initial, 2 units or less for initial 2 doses due to possible anaphylactoid reaction<\/li><li><b>Hodgkin's disease:<\/b> treatment, 10 to 20 units\/m(2) (0.25 to 0.5 units\/kg) IV\/IM\/subQ once or twice weekly<\/li><li><b>Hodgkin's disease:<\/b> maintenance, following a 50% response, use a maintenance dose of 1 unit IV\/IM once daily OR 5 units once weekly<\/li><li><b>Malignant effusion - Peritoneal effusion:<\/b> optimal dosing and timing not determined<\/li><li><b>Malignant melanoma:<\/b> optimal dosing and timing not yet defined; clinical trials have used 0.5 units INTRALESIONALLY for tumors up to 100 mm(3) in size, 0.75 units for tumors 100 to 150 mm(3), 1 unit for tumors 150 to 500 mm(3), 1.5 units for tumors 500 to 1000 mm(3), 2 units for tumors 1000 to 2000 mm(3), 2.5 units for tumors 2000 to 3000 mm(3), 3 units for tumors 3000 to 4000 mm(3), 3.5 units for tumors 4000 to 5000 mm(3), and 4 units for tumors larger than 5000 mm(3); lidocaine 1% with epinephrine solution was injected around  the site, followed by 6 to 8 99-microsecond pulses of  electricity at an amplitude of 1.3 kV\/cm using either electrodes consisting of 2 parallel stainless steel plates mounted on a vernier caliper or a circular array of 6 needles<\/li><li><b>Malignant pericardial effusion:<\/b> optimal dosing and timing not determined<\/li><li><b>Malignant tumor of thyroid gland:<\/b> optimal dosing and timing has not been defined<\/li><li><b>Mycosis fungoides, Advanced stage, in combination with other agents:<\/b> optimal dose and timing not defined<\/li><li><b>Neoplastic pleural effusion:<\/b> 60 units INTRAPLEURAL injection single bolus dose dissolved in 50 to 100 mL NS<\/li><li><b>Non-Hodgkin's lymphoma:<\/b> initial, 2 units or less for initial 2 doses due to possible anaphylactoid reaction<\/li><li><b>Non-Hodgkin's lymphoma:<\/b> 10 to 20 units\/m(2) (0.25 to 0.5 units\/kg) IV\/IM\/SC once or twice weekly<\/li><li><b>Osteosarcoma of bone:<\/b> Optimal dose and timing of bleomycin has not been defined<\/li><li><b>Squamous cell carcinoma of cervix:<\/b> 10 to 20 units\/m(2) (0.25 to 0.5 units\/kg) IV\/IM\/subQ once or twice weekly<\/li><li><b>Squamous cell carcinoma of nasopharynx:<\/b> 10 to 20 units\/m(2) (0.25 to 0.5 units\/kg) IV\/IM\/subQ once or twice weekly<\/li><li><b>Squamous cell carcinoma of penis:<\/b> 10 to 20 units\/m(2) (0.25 to 0.5 units\/kg) IV\/IM\/subQ once or twice weekly<\/li><li><b>Squamous cell carcinoma of the head and neck:<\/b> 10 to 20 units\/m(2) (0.25 to 0.5 units\/kg) IV\/IM\/subQ once or twice weekly<\/li><li><b>Squamous cell carcinoma of vulva:<\/b> 10 to 20 units\/m(2) (0.25 to 0.5 units\/kg) IV\/IM\/subQ once or twice weekly<\/li><li><b>Testicular cancer:<\/b> 10 to 20 units\/m(2) (0.25 to 0.5 units\/kg) IV\/IM\/subQ once or twice weekly<\/li><li><b>Verruca vulgaris:<\/b> 1 unit\/mL (single injection) by a multiple puncture technique using a bifurcated vaccination needle.<\/li><\/ul>"},{"id":"80775-s-1-5","title":"Pediatric Dosing","mono":"safety and effectiveness have not been established in pediatric patients "},{"id":"80775-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>renal impairment:<\/b> CrCl 40 to 50 mL\/min (70% dose); CrCl 30 to 40 mL\/min (60% dose); CrCl 20 to 30 mL\/min (55% dose); CrCl 10 to 20 (45% dose); CrCl 5 to 10 mL\/min (40% dose)<\/li><li><b>hemodialysis:<\/b> no dosage supplementation is needed in patients following hemodialysis<\/li><\/ul>"},{"id":"80775-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Hodgkin's disease<\/li><li>Neoplastic pleural effusion<\/li><li>Non-Hodgkin's lymphoma<\/li><li>Squamous cell carcinoma of cervix<\/li><li>Squamous cell carcinoma of nasopharynx<\/li><li>Squamous cell carcinoma of penis<\/li><li>Squamous cell carcinoma of the head and neck<\/li><li>Squamous cell carcinoma of vulva<\/li><li>Testicular cancer<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>AIDS-related Kaposi's sarcoma<\/li><li>Carcinoma of esophagus<\/li><li>Cystic craniopharyngioma<\/li><li>Germ cell tumor of ovary<\/li><li>Gestational trophoblastic neoplasia<\/li><li>Malignant effusion - Peritoneal effusion<\/li><li>Malignant melanoma<\/li><li>Malignant pericardial effusion<\/li><li>Malignant tumor of thyroid gland<\/li><li>Mycosis fungoides, Advanced stage, in combination with other agents<\/li><li>Osteosarcoma of bone<\/li><li>Verruca vulgaris<\/li><\/ul>"}]},{"id":"80775-s-2","title":"Black Box Warning","mono":"<b>Injection (Powder for Solution)<\/b><br\/>Pulmonary fibrosis is the most severe toxicity and its most frequent presentation is pneumonitis occasionally progressing to pulmonary fibrosis. Its occurrence is higher in elderly patients and in those receiving greater than 400 units total dose, but pulmonary toxicity has been observed in young patients and those treated with low doses. A severe idiosyncratic reaction consisting of hypotension, mental confusion, fever, chills, and wheezing has been reported in lymphoma patients treated with bleomycin for injection.<br\/>"},{"id":"80775-s-3","title":"Contraindications\/Warnings","sub":[{"id":"80775-s-3-9","title":"Contraindications","mono":"hypersensitivity or idiosyncratic reactions to bleomycin products<br\/>"},{"id":"80775-s-3-10","title":"Precautions","mono":"<ul><li>renal impairment<\/li><li>carcinogenic potential of bleomycin<\/li><li>benefit outweighs toxicity<\/li><li>pulmonary disease<\/li><li>bleomycin should be administered in a proper medical setting (eg, hospital) by qualified health providers<\/li><\/ul>"},{"id":"80775-s-3-11","title":"Pregnancy Category","mono":"<ul><li>Bleomycin: D (FDA)<\/li><li>Bleomycin: D (AUS)<\/li><\/ul>"},{"id":"80775-s-3-12","title":"Breast Feeding","mono":"<ul><li>Bleomycin: WHO: Avoid breastfeeding.<\/li><li>Bleomycin: Micromedex: Infant risk cannot be ruled out.<\/li><\/ul>"}]},{"id":"80775-s-4","title":"Drug Interactions","sub":[{"id":"80775-s-4-13","title":"Contraindicated","mono":"<ul><li>Brentuximab Vedotin (probable)<\/li><li>Rotavirus Vaccine, Live (established)<\/li><\/ul>"},{"id":"80775-s-4-14","title":"Major","mono":"<ul><li>Adenovirus Vaccine Type 4, Live (established)<\/li><li>Adenovirus Vaccine Type 7, Live (established)<\/li><li>Bacillus of Calmette and Guerin Vaccine, Live (established)<\/li><li>Influenza Virus Vaccine, Live (established)<\/li><li>Measles Virus Vaccine, Live (established)<\/li><li>Mumps Virus Vaccine, Live (established)<\/li><li>Poliovirus Vaccine, Live (established)<\/li><li>Rubella Virus Vaccine, Live (established)<\/li><li>Smallpox Vaccine (established)<\/li><li>Typhoid Vaccine (established)<\/li><li>Varicella Virus Vaccine (established)<\/li><li>Yellow Fever Vaccine (established)<\/li><\/ul>"},{"id":"80775-s-4-15","title":"Moderate","mono":"<ul><li>Fosphenytoin (probable)<\/li><li>Phenytoin (probable)<\/li><\/ul>"}]},{"id":"80775-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Hyperkeratosis, Hyperpigmentation of skin<\/li><li><b>Gastrointestinal:<\/b>Stomatitis<\/li><li><b>Respiratory:<\/b>Interstitial pneumonia<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Arterial thrombosis, Cerebrovascular accident, Myocardial infarction, Raynaud's phenomenon<\/li><li><b>Dermatologic:<\/b>Gangrenous disorder<\/li><li><b>Hematologic:<\/b>Thrombotic microangiopathy<\/li><li><b>Hepatic:<\/b>Hepatotoxicity<\/li><li><b>Immunologic:<\/b>Idiosyncratic drug effect (1%)<\/li><li><b>Neurologic:<\/b>Cerebral edema, Encephalopathy<\/li><li><b>Renal:<\/b>Hemorrhagic cystitis, Nephrotoxicity<\/li><li><b>Respiratory:<\/b>Pulmonary fibrosis<\/li><li><b>Other:<\/b>Hyperpyrexia<\/li><\/ul>"},{"id":"80775-s-6","title":"Drug Name Info","sub":{"0":{"id":"80775-s-6-17","title":"US Trade Names","mono":"Blenoxane<br\/>"},"2":{"id":"80775-s-6-19","title":"Class","mono":"Antibiotic<br\/>"},"3":{"id":"80775-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"80775-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},{"id":"80775-s-7","title":"Mechanism Of Action","mono":"Evidence indicates that the primary mechanism of action of bleomycin is inhibition of DNA synthesis via single-strand breaks and, to a lesser extent, double-strand breaks. Inhibition of RNA and protein synthesis may also occur. Bleomycin acts as a sclerosing agent when administered intrapleurally to treat malignant pleural effusion.<br\/>"},{"id":"80775-s-8","title":"Pharmacokinetics","sub":[{"id":"80775-s-8-23","title":"Absorption","mono":"<ul><li>Tmax, IM: 30 to 60 min<\/li><li>Tmax, Intraperitoneal: 30 to 60 min<\/li><li>Tmax, Intrapleural: 30 to 60 min<\/li><li>Tmax, SubQ: 30 to 60 min<\/li><li>Bioavailability, IM: 100%<\/li><li>Bioavailability, Intraperitoneal: 45%  to 80%<\/li><li>Bioavailability, Intrapleural: 40%  to 45%<\/li><li>Bioavailability, SubQ: 70%<\/li><\/ul>"},{"id":"80775-s-8-24","title":"Distribution","mono":"Vd: 17.5 L\/m(2) <br\/>"},{"id":"80775-s-8-25","title":"Metabolism","mono":"Various tissues: low to high extent of metabolism depending on tissue content of cytosolic cysteine proteinase <br\/>"},{"id":"80775-s-8-26","title":"Excretion","mono":"<ul><li>Renal, IV administration: 65%<\/li><li>Renal, intrapleural administration: 40%<\/li><li>Renal, pediatric patients: 50%<\/li><li>Renal, moderately severe renal failure: less than 20% of the dose<\/li><li>Renal clearance: 23 mL\/min\/m(2)<\/li><li>Dialyzable: No<\/li><li>Total body clearance: adults, 51 mL\/min\/m(2); children less than 3 yr, 71 mL\/min\/m(2)<\/li><\/ul>"},{"id":"80775-s-8-27","title":"Elimination Half Life","mono":"<ul><li>2  to 8.6 hr<\/li><li>increases exponentially as CrCl decreases<\/li><\/ul>"}]},{"id":"80775-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/><ul><li>use proper procedures for handling and disposal of bleomycin<\/li><li>do not reconstitute or dilute with D5W or other dextrose-containing diluents<\/li><\/ul><\/li><li><b>Intramuscular<\/b><br\/>reconstitute the 15-units and 30-units vial with 1 mL to 5 mL and 2 mL to 10 mL, respectively, with NS, sterile bacteriostatic water of injection or sterile water for injection.<br\/><\/li><li><b>Intrapleural<\/b><br\/><ul><li>dissolve in 50 to 100 mL of NS and administer through a thoracostomy tube<\/li><li>administer through a thoracotomy tube, following drainage of pleural fluid and confirmation of complete lung expansion. Clamp the thoracotomy tube and move the patient from supine to left and right lateral positions (several times) for next 4 hours; reestablish suction<\/li><\/ul><\/li><li><b>Intravenous<\/b><br\/><ul><li>reconstitute 15-units and 30-units vial with 5 mL and 10 mL of NS, respectively<\/li><li>administer intravenously slowly over 10 min<\/li><\/ul><\/li><li><b>Subcutaneous<\/b><br\/>reconstitute the 15-units and 30-units vial with 1 mL to 5 mL and 2 mL to 10 mL, respectively, with NS, sterile bacteriostatic water of injection or sterile water for injection.<br\/><\/li><\/ul>"},{"id":"80775-s-10","title":"Monitoring","mono":"<ul><li>evidence of tumor response may indicate efficacy<\/li><li>chest roentgenograms; every 1 to 2 weeks during therapy; especially in the elderly<\/li><li>renal function; in patients with CrCl less than 50 mL\/min, and consider in elderly patients<\/li><li>signs\/symptoms of idiosyncratic reactions (hypotension, mental confusion, fever, chills, and wheezing); after the first and second doses<\/li><li>pulmonary diffusion capacity for carbon dioxide; monthly if used to detect pulmonary toxicities<\/li><\/ul>"},{"id":"80775-s-11","title":"How Supplied","mono":"<b>Generic<\/b><br\/>Injection Powder for Solution: 15 U, 30 U<br\/>"},{"id":"80775-s-12","title":"Toxicology","sub":[{"id":"80775-s-12-31","title":"Clinical Effects","mono":"<b>BLEOMYCIN<\/b><br\/> OVERDOSE: An extension of adverse effects. ADVERSE EFFECTS: Pulmonary toxicity appears to be the primary dose-limiting effect; pulmonary fibrosis, N\/V, weight loss, stomatitis, dermatitis, mucositis, alopecia, fever, renal and hepatic toxicity (rare effects); a severe idiosyncratic condition (mental confusion, hypotension, fever, chills, and wheezing) in approx 1% of lymphoma patients receiving bleomycin. <br\/>"},{"id":"80775-s-12-32","title":"Treatment","mono":"<b>BLEOMYCIN<\/b><br\/><ul><li>Hypotensive episode: IV 0.9% NaCl, dopamine, norepinephrine.<\/li><li>Corticosteroid: High doses may be effective in bleomycin-induced pulmonary toxicity.<\/li><li>Intrathecal injection:  Inadvertent intrathecal injection has been reported with bleomycin. This treatment information was derived from experience with other antineoplastics. Immediately drain at least 20 mL CSF; drainage of up to 70 mL has been tolerated in adults. Follow with CSF exchange (remove serial 20 mL aliquots CSF and replace with equivalent volumes of warmed, preservative free normal saline or lactated ringers). For large overdoses, consult a neurosurgeon for placement of a ventricular catheter and begin ventriculolumbar perfusion (infuse warmed preservative free normal saline or lactated ringers through ventricular catheter, drain fluid from lumbar catheter; typical volumes 80 to 150 mL\/hr). Dexamethasone 4 mg intravenously every 6 hours to prevent arachnoiditis.<\/li><li>Monitoring of patient: Vital signs, fluid and electrolytes status; chest radiograph, pulse oximetry and\/or arterial blood gases in patients with acute respiratory signs or symptoms.<\/li><\/ul>"},{"id":"80775-s-12-33","title":"Range of Toxicity","mono":"<b>BLEOMYCIN<\/b><br\/>A toxic dose has not been established. An increased risk of pulmonary toxicity with doses of 400 units or higher. However, low cumulative doses (range 34 to 120 units total dose) of bleomycin have resulted in severe pulmonary toxicity in both adults and children.<br\/>"}]},{"id":"80775-s-13","title":"Clinical Teaching","mono":"<ul><li>Counsel patient to avoid vaccines during therapy due to drug-induced immunosuppression.<\/li><li>This drug may cause alopecia, a skin reaction (erythema, rash, striae, vesiculation, hyperpigmentation, skin tenderness), shivering, nausea, vomiting, stomatitis, confusion, fever, hypotension, myocardial infarction, cerebrovascular accident, hepatotoxicity, or nephrotoxicity.<\/li><li>Instruct patient to report signs\/symptoms of pulmonary toxicity, which usually presents as pneumonitis and possibly progresses to pulmonary fibrosis.<\/li><li>Advise patient to report signs\/symptoms of a severe idiosyncratic reaction (hypotension, mental confusion, fever, chills, wheezing).<\/li><li>Patient should also report signs\/symptoms of infection.<\/li><li>Patient should not drink alcohol or smoke while taking this drug.<\/li><\/ul>"}]}